.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The REACT trial evaluated whether adding the oral phosphodiesterase-4 inhibitor roflumilast to inhaled maintenance therapy could reduce exacerbations in patients with severe COPD, chronic bronchitis, and a history of frequent exacerbations. Participants received roflumilast or placebo alongside background inhaled corticosteroid/LABA therapy, with some also receiving tiotropium. The investigators found a reduction in exacerbation frequency with roflumilast, with the clearest signal emerging in analyses that accounted for treatment adherence and protocol factors. The study also highlighted an important clinical trade-off: adverse events and treatment discontinuations were more common with roflumilast. For HCPs, the message is one of phenotype-directed escalation rather than broad use. Roflumilast is most relevant when chronic bronchitis, severe airflow limitation, and recurrent exacerbations persist despite optimized inhaled therapy. Tolerability and patient selection matter because gastrointestinal and other adverse effects can limit long-term use. This evidence fits the conference focus on COPD beyond spirometry, where exacerbation pattern, symptom phenotype, exposure history, and treatment response help guide more individualized management.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The REACT trial evaluated whether adding the oral phosphodiesterase-4 inhibitor roflumilast to inhaled maintenance therapy could reduce exacerbations in patients with severe COPD, chronic bronchitis, and a history of frequent exacerbations. Participants received roflumilast or placebo alongside background inhaled corticosteroid/LABA therapy, with some also receiving tiotropium. The investigators found a reduction in exacerbation frequency with roflumilast, with the clearest signal emerging in analyses that accounted for treatment adherence and protocol factors. The study also highlighted an important clinical trade-off: adverse events and treatment discontinuations were more common with roflumilast. For HCPs, the message is one of phenotype-directed escalation rather than broad use. Roflumilast is most relevant when chronic bronchitis, severe airflow limitation, and recurrent exacerbations persist despite optimized inhaled therapy. Tolerability and patient selection matter because gastrointestinal and other adverse effects can limit long-term use. This evidence fits the conference focus on COPD beyond spirometry, where exacerbation pattern, symptom phenotype, exposure history, and treatment response help guide more individualized management.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
